Astellas will expand manufacturing capabilities for aseptic drug products, to reinforce stable production for global supply, and to accelerate the development and commercialization of new drugs by the new lines.
Astellas is developing new drugs utilizing new modalities and technologies based on its Focus Area approach. These new lines for aseptic drug products allow flexibility to manufacture not only antibodies, but also new modalities that require high technology in the future with some modification of the facility. With these new production lines, Astellas aims to improve its own manufacturing capabilities and strengthen its seamless and stable manufacturing system from development to commercialization phases.
About Astellas
Cautionary Notes
In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.
Contact:
Tel: +81-3-3244-3201
Fax: +81-3-5201-7473
(C) 2021 Electronic News Publishing, source